Sub-contract approach for VISITECT® COVID-19 antigen test
Omega Diagnostics Gp (ODX.L) Speculation regarding a potential fundraise
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products.
Omega Diagnostics Gp (ODX.L) CE-Mark for self-test for VISITECT® COVID-19 test
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products announces that it has successfully CE marked its VISITECT®
Omega Diagnostics Gp (ODX.L) Speculation regarding a potential fundraise
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products.
Omega Diagnostics Gp (ODX.L) Directorate Change
Omega (AIM: ODX), the medical diagnostics company focused on Global Health (CD4 and COVID-19) and Health and Nutrition, announces that Colin King, Chief Executive Officer, has notified the Board that
Omega Diagnostics Gp (ODX.L) Confirmation of detection of Omicron variant
VISITECT® COVID-19 antigen test performs with the same high accuracy on the Omicron variant
Omega Diagnostics Gp (ODX.L) DHSC contract update
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, provides an update in relation to the Company’s contract
Braveheart Inv Group (BRH.L) Operational update on Paraytec
Braveheart Investment Group plc (AIM: BRH), is pleased to provide the following update on Paraytec, a company within the Group’s investment portfolio.
Omega Diagnostics is confident that it can stem losses as the sales momentum increases
Omega Diagnostics, a medical testing company, has reported greater interim losses despite an increase in revenues.
Braveheart Inv Group (BRH.L) Video from The University of Sheffield re Paraytec
Braveheart Investment Group (AIM: BRH) announces that, the Group has been advised that The University of Sheffield has produced a brief video regarding the work it has been doing with
Omega Diagnostics Gp (ODX.L) Half-year Report
INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2021
Omega Diagnostics Gp (ODX.L) Notice of Results and Investor Presentation
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, announces it will release its interim results for the